vimarsana.com

Latest Breaking News On - Sruthi narasimha chari - Page 1 : vimarsana.com

Fitch revises Egypt s outlook to positive on reduced external financing risks

Fitch revises Egypt s outlook to positive on reduced external financing risks

Global ratings agency Fitch revised Egypt s outlook to positive from stable on Friday. The agency affirmed Eygpt s rating at B- , citing reduced external financing risks and stronger. -May 03, 2024 at 05:08 pm EDT - MarketScreener

Neurocrine Biosciences Huntington s disease drug gets FDA approval

By Sruthi Narasimha Chari (Reuters) -The U.S. Food and Drug Administration (FDA) has approved the granule formulation of Neurocrine Biosciences' Ingrezza drug to treat movement disorders associated with Huntington's disease (HD), the company said on Tu.

Insurer Aflac beats profit estimates on higher US premiums

Insurance provider Aflac reported first-quarter profit above analysts estimates on Wednesday, helped by improved premiums earned in the United States. Aflac s shares rose 1.42% in.

Dexcom s profit beats estimates on strong glucose monitor demand

Dexcom beat Wall Street expectations for first-quarter profit on Thursday, helped by strong demand for a new version of its continuous glucose monitors, but its shares slid 7% after the bell as annual.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.